Project: Study of Pharmacogenetics of ARVs treatment outcomes in Mali, West Africa

Acronym SPATOMA (Reference Number: TMA2016CDF-1566)
Duration 01/07/2018 - 30/06/2021
Project Topic The introduction of highly active antiretroviral therapy (HAART) in the management of acquired immunodeficiency syndrome (AIDS) reduced the morbidity and mortality related to the human immunodeficiency virus infection and transformed AIDS into a chronic disease worldwide. However, the occurrence in certain patients of invalidating side effects or resistance related to antiretroviral (ARVs) treatment may be a source of nonadherence and results in an inadequate response. These differences in treatment response observed in patients could be due to various factors (age, gender, and ethnicity). However, genetic factors play a significant role in the variability of the response to treatment. Like other drugs, ARVs are metabolized by enzymes encoded by polymorphic genes. Thus, inter-individual differences in DNA sequence as a result of single nucleotide polymorphisms (SNP) may explain the variability of therapeutic responses. The most relevant enzymatic classes influencing drug metabolism are the cytochrome P450, the multidrug resistance gene-1 (MDR-1) and the glutathione S-transferase (GST). This project will focus on the pharmacogenetics aspects of the ARV treatment, and will investigate the impact of selected SNPs from the above mentioned three major classes of drug metabolising enzymes.
Network EDCTP2
Call Career Development Fellowships 2016

Project partner

Number Name Role Country
1 Université des Sciences, des Techniques et des Technologies de Bamako Coordinator Mali